Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark Office (USPTO) has granted a notice of allowance (NOA) to Arrowhead Research's new formulation of dynamic polyconjugate (DPC) siRNA delivery system.
Subscribe to our email newsletter
The patent application No.13/032,029 covers claims for protecting an siRNA delivery system consisting of a liver-targeted endosomolytic polymer, which is co-administered with an RNAi polynucleotide (siRNA) conjugated to a lipophilic or carbohydrate targeting moiety such as cholesterol
As demonstrated in pre-clinical studies, a >500-fold increase in the potency was observed when liver-targeted polymer with siRNA conjugated to a cholesterol were co-injected together, when compared to the siRNA-cholesterol alone.
Arrowhead president and CEO Chris Anzalone said the patent broadly covers compositions, methods, and uses for a new formulation of DPC siRNA delivery platform, where attachment of siRNA and delivery vehicle is not required to produce high-level, efficient knockdown of target genes.
"The new IP expands the DPC platform and is used in Arrowhead’s ARC-520 candidate in development for chronic hepatitis B virus (HBV) infection," Anzalone added.
"The underlying technology enables us to create candidates with highly potent silencing activity and attractive manufacturing qualities.
"We continue to work towards a planned phase 1 trial of ARC-520, and are pleased to announce that we had a very productive pre-IND meeting with the FDA, which allows us to maintain our timeline to file an IND in Q2 2013."